Market Mover: Savara (SVRA) Gains at Midday June 21

Equities Staff  |

Savara Inc (NASDAQ: SVRA) has climbed $0.081 (6.23%) and is currently sitting at $1.38, as of 12:02:25 est on June 21.

30,639 shares have been traded today.

The Company has decreased 6.47% over the last 5 days and shares lost 5.11% over the last 30 days.

Savara anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on Savara visit the company profile.

About Savara Inc

Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

To get more information on Savara Inc and to follow the company's latest updates, you can visit the company's profile page here: Savara Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content